GENPREX INC (GNPX) Stock Price & Overview
NASDAQ:GNPX • US3724463027
Current stock price
The current stock price of GNPX is 1.45 USD. Today GNPX is down by -5.84%. In the past month the price decreased by -25.64%. In the past year, price decreased by -89.12%.
GNPX Key Statistics
- Market Cap
- 13.108M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -453.50
- Dividend Yield
- N/A
GNPX Stock Performance
GNPX Stock Chart
GNPX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GNPX. When comparing the yearly performance of all stocks, GNPX is a bad performer in the overall market: 96.96% of all stocks are doing better.
GNPX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNPX. The financial health of GNPX is average, but there are quite some concerns on its profitability.
GNPX Earnings
GNPX Forecast & Estimates
GNPX Groups
Sector & Classification
GNPX Financial Highlights
Over the last trailing twelve months GNPX reported a non-GAAP Earnings per Share(EPS) of -453.5. The EPS increased by 60.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -458.87% | ||
| ROE | -1262.44% | ||
| Debt/Equity | 0 |
GNPX Ownership
GNPX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.93 | 365.463B | ||
| AMGN | AMGEN INC | 15.01 | 184.669B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 173.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.325B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 80.669B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.27 | 43.81B | ||
| INSM | INSMED INC | N/A | 35.309B | ||
| NTRA | NATERA INC | N/A | 29.036B | ||
| BIIB | BIOGEN INC | 10.72 | 25.293B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.53B | ||
| MRNA | MODERNA INC | N/A | 19.261B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.898B | ||
| INCY | INCYTE CORP | 12.39 | 18.878B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GNPX
Company Profile
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Company Info
IPO: 2018-03-29
GENPREX INC
3300 Bee Cave Road, Suite 650-227
Austin TEXAS 78712 US
CEO: J. Rodney Varner
Employees: 15
Phone: 18777744679
GENPREX INC / GNPX FAQ
What does GENPREX INC do?
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Can you provide the latest stock price for GENPREX INC?
The current stock price of GNPX is 1.45 USD. The price decreased by -5.84% in the last trading session.
What is the dividend status of GENPREX INC?
GNPX does not pay a dividend.
How is the ChartMill rating for GENPREX INC?
GNPX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is GNPX stock listed?
GNPX stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for GENPREX INC?
GENPREX INC (GNPX) operates in the Health Care sector and the Biotechnology industry.
Should I buy GNPX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNPX.